Analysts think ANRO stock price could increase by 358%
May 15, 2025, 11:25 AM
21.12%
What does ANRO do
Alto Neuroscience, a clinical-stage biopharmaceutical company based in Los Altos, California, focuses on developing psychiatric drugs using its Precision Psychiatry Platform. The company has five clinical-stage assets targeting depression and schizophrenia, with an IPO on February 2, 2024.
8 analysts think ANRO stock price will increase by 358.43%. The current median analyst target is $10.20 compared to a current stock price of $2.23. The lowest analysts target is $4.04 and the highest analyst target is $18.90.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
